Capricor Therapeutics, Inc. $CAPR Stock: Oppenheimer & Co. Inc. Grows Position

Oppenheimer & Co. Inc. lifted its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 169.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 203,781 shares of the biotechnology company’s stock after buying an additional 128,067 shares during the period. Oppenheimer & Co. Inc.’s holdings in Capricor Therapeutics were worth $1,930,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Walleye Capital LLC purchased a new stake in Capricor Therapeutics during the 1st quarter valued at about $5,397,000. Bank of America Corp DE increased its stake in Capricor Therapeutics by 672.0% in the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after purchasing an additional 361,664 shares during the period. Montanova Capital LLC increased its stake in Capricor Therapeutics by 7.2% in the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after purchasing an additional 274,184 shares during the period. Ally Bridge Group NY LLC purchased a new position in Capricor Therapeutics in the 1st quarter worth approximately $3,463,000. Finally, Bank of New York Mellon Corp bought a new stake in Capricor Therapeutics in the second quarter valued at approximately $3,895,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $6.38 on Friday. The stock has a market capitalization of $370.93 million, a PE ratio of -2.60 and a beta of 0.61. Capricor Therapeutics, Inc. has a 1 year low of $2.96 and a 1 year high of $40.37. The business’s 50-day moving average is $8.06 and its 200 day moving average is $20.60.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). As a group, equities research analysts anticipate that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CAPR shares. Maxim Group lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. JonesTrading cut shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. B. Riley Financial raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $5.00 to $21.00 in a research note on Monday, September 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Finally, Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a report on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of “Hold” and an average target price of $30.25.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.